Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: A double-blind randomized controlled pilot trial

Nutrition Journal

Volumn 11, Issue 1, 2012, Pages

  González Hernández, Luz A ^a   Jave Suarez, Luis F ^b   Fafutis Morris, Mary ^a   Montes Salcedo, Karina E ^a   Valle Gutierrez, Luis G ^a   Campos Loza, Ariel E ^a   Enciso Gómez, Luis Fermin ^a   Andrade Villanueva, Jaime F ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; INTERLEUKIN 6; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

ADULT; AGED; ARTICLE; BACTERIAL LOAD; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DOUBLE BLIND PROCEDURE; FECES; FEMALE; FLATULENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; INFLAMMATION; MALE; METEORISM; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CD4 LYMPHOCYTE COUNT; CYTOKINES; DISEASE PROGRESSION; DNA, BACTERIAL; DOUBLE-BLIND METHOD; FECES; FEMALE; HIV ENTEROPATHY; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS RHAMNOSUS; MALE; MEXICO; PILOT PROJECTS; PREBIOTICS; PROBIOTICS; QUALITY OF LIFE; YOUNG ADULT;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM; CLOSTRIDIUM;

EID: 84867897414     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-11-90     Document Type: Article

References (40)

1. In HIV-1 pathogenesis the die is cast during primary infection. Centlivre M, Sala M, Wain-Hobson S, Berkhout B, AIDS 2007 21 1 1 11 10.1097/QAD. 0b013e3280117f7f 17148962 (Pubitemid 44912531)
2. HIV infection and the gastrointestinal immune system. Brenchley JM, Douek DC, Mucosal Immunol 2008 1 1 23 30 10.1038/mi.2007.1 19079157
3. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. J Exp Med 2004 200 6 749 759 10.1084/jem.20040874 15365096 (Pubitemid 39299461)
4. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. J Exp Med 2004 200 6 761 770 10.1084/jem.20041196 15365095 (Pubitemid 39299462)
5. Lymphocyte-dendritic cell interactions and mucosal acquisition of SIV/HIV infection. Turville SG, Peretti S, Pope M, Curr Opin HIV AIDS 2006 1 1 3 9 10.1097/01.COH.0000194109.14601.20 19372776
6. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, et al. J Virol 2006 80 16 8236 8247 10.1128/JVI.00120-06 16873279 (Pubitemid 44182323)
7. HIV infection and the gastrointestinal tract. Kotler DP, AIDS 2005 19 2 107 117 10.1097/00002030-200501280-00002 15668535 (Pubitemid 40409529)
8. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Nat Med 2006 12 12 1365 1371 17115046 (Pubitemid 44924494)
9. HIV disease: fallout from a mucosal catastrophe? Brenchley JM, Price DA, Douek DC, Nat Immunol 2006 7 3 235 239 10.1038/ni1316 16482171
10. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. J Infect Dis 2009 199 8 1177 1185 10.1086/597476 19265479
11. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. J Infect Dis 2003 187 10 1534 1543 10.1086/374786 12721933 (Pubitemid 36578959)
12. Microbial influences in inflammatory bowel diseases. Sartor RB, Gastroenterology 2008 134 2 577 594 10.1053/j.gastro.2007.11.059 18242222 (Pubitemid 351173057)
13. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Wolf BW, Wheeler KB, Ataya DG, Garleb KA, Food Chem Toxicol 1998 36 12 1085 1094 10.1016/S0278- 6915(98)00090-8 9862651 (Pubitemid 29002891)
14. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. Hummelen R, Vos AP, vant Land B, van Norren K, Reid G, Int Rev Immunol 2010 29 5 485 513 10.3109/08830185.2010.505310 20839912
15. Use of probiotics in HIV-infected children: a randomized double-blind controlled study. Trois L, Cardoso EM, Miura E, J Trop Pediatr 2008 54 1 19 24 17878180 (Pubitemid 351234405)
16. Probiotics: definition, sources, selection, and uses. Sanders ME, Clin Infect Dis 2008 46 Suppl 2 58 S61 discussion S144-51 18181724
17. Mechanisms of action of probiotics. Walker WA, Clin Infect Dis 2008 46 Suppl 2 87 S91 discussion S144-51 18181730
18. Probiotics: facts and myths. Senok AC, Ismaeel AY, Botta GA, Clin Microbiol Infect 2005 11 12 958 966 10.1111/j.1469-0691.2005.01228.x 16307549 (Pubitemid 41748929)
19. Probiotics and their fermented food products are beneficial for health. Parvez S, Malik KA, Ah Kang S, Kim HY, J Appl Microbiol 2006 100 6 1171 1185 10.1111/j.1365-2672.2006.02963.x 16696665 (Pubitemid 43739184)
20. Dietary fibres as prebiotics: implications for colorectal cancer. Lim CC, Ferguson LR, Tannock GW, Mol Nutr Food Res 2005 49 6 609 619 10.1002/mnfr.200500015 15864790 (Pubitemid 40853707)
21. Influence of fructooligosaccharides on Peyers patch lymphocyte numbers in healthy and endotoxemic mice. Manhart N, Spittler A, Bergmeister H, Mittlbock M, Roth E, Nutrition 2003 19 7-8 657 660 12831954 (Pubitemid 36794295)
22. Molecular structures of fructans from Agave tequilana Weber var. azul. Lopez MG, Mancilla-Margalli NA, Mendoza-Diaz G, J Agric Food Chem 2003 51 27 7835 7840 10.1021/jf030383v 14690361
23. Physiological effects of dietary fructans extracted from Agave tequilana Gto. and Dasylirion spp. Urias-Silvas JE, Cani PD, Delmee E, Neyrinck A, Lopez MG, Delzenne NM, Br J Nutr 2008 99 2 254 261 17711612
24. Impact of the intestinal microbiota on the development of mucosal defense. Gaskins HR, Croix JA, Nakamura N, Nava GM, Clin Infect Dis 2008 46 Suppl 2 80 S86 discussion S144-51 18181729
25. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Am J Gastroenterol 2000 95 4 999 1007 10.1111/j.1572-0241.2000.01941.x 10763950 (Pubitemid 30196737)
26. Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study. Rachlis A, Gill J, Baril JG, LeBlanc RP, Trottier B, MacLeod J, et al. HIV Clin Trials 2005 6 4 203 212 10.1310/2BJL-J62N-BFJX-4995 16323322 (Pubitemid 41601132)
27. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression. Ling B, Veazey RS, Hart M, Lackner AA, Kuroda M, Pahar B, et al. AIDS 2007 21 18 2377 2385 10.1097/QAD.0b013e3282f08b32 18025874 (Pubitemid 350145169)
28. Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR. Delroisse JM, Boulvin AL, Parmentier I, Dauphin RD, Vandenbol M, Portetelle D, Microbiol Res 2008 163 6 663 670 10.1016/j.micres.2006.09.004 19216105
29. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R, Appl Environ Microbiol 2004 70 12 7220 7228 10.1128/AEM.70.12.7220-7228.2004 15574920 (Pubitemid 39643786)
30. The mucosal barrier and immune activation in HIV pathogenesis. Brenchley JM, Douek DC, Curr Opin HIV AIDS 2008 3 3 356 361 10.1097/COH.0b013e3282f9ae9c 19372990 (Pubitemid 351521021)
31. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. Salminen MK, Tynkkynen S, Rautelin H, Poussa T, Saxelin M, Ristola M, et al. HIV Clin Trials 2004 5 4 183 191 10.1310/6F83-N39Q-9PPP-LMVV 15472792 (Pubitemid 39467964)
32. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G, J Clin Gastroenterol 2008 42 3 239 243 18223503 (Pubitemid 351301487)
33. Probiotic use in clinical practice: what are the risks? Boyle RJ, Robins-Browne RM, Tang ML, Am J Clin Nutr 2006 83 6 1256 1264 quiz 446-7 16762934 (Pubitemid 44713053)
34. The safety of probiotics. Snydman DR, Clin Infect Dis 2008 46 Suppl 2 104 S111 discussion S44-51 18181712
35. Probiotics in the United States. Vanderhoof JA, Young R, Clin Infect Dis 2008 46 Suppl 2 67 S72 discussion S144-51 18181726
36. Th17, gut, and HIV: therapeutic implications. Hunt PW, Curr Opin HIV AIDS 2010 5 2 189 193 10.1097/COH.0b013e32833647d9 20543599
37. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. PLoS Med 2008 5 10 203 10.1371/journal.pmed.0050203 18942885
38. Update on cardiovascular complications in HIV infection. Currier JS, Top HIV Med 2009 17 3 98 103 19675367
39. Complications of HIV disease and antiretroviral therapy. Currier JS, Havlir DV, Top HIV Med 2009 17 2 57 67 19401608
40. Pharmacogenetics of adverse effects due to antiretroviral drugs. Vidal F, Gutierrez F, Gutierrez M, Olona M, Sanchez V, Mateo G, et al. AIDS Rev 2010 12 1 15 30 20216907